Reinventing the ACE inhibitors: some old and new implications of ACE inhibition (Q37632261)

21 August 2017

1 reference

title

Reinventing the ACE inhibitors: some old and new implications of ACE inhibition (English)

1 reference

21 August 2017

Kashif Hanif

1

1 reference

PubMed ID

19911001

21 August 2017

Hemant K Bid

series ordinal

2

1 reference

PubMed ID

19911001

21 August 2017

Rituraj Konwar

series ordinal

3

1 reference

21 August 2017

13 November 2009

1 reference

21 August 2017

Hypertension Research

1 reference

21 August 2017

33

1 reference

21 August 2017

1

1 reference

21 August 2017

11-21

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2009.184

21 August 2017

0 references

cites work

Angiotensin-Converting Enzyme Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

The effect of captopril on the reflex control heart rate: possible mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Hypertension in diabetic patients: an update of interventional studies to preserve renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

NAD(P)H oxidase: role in cardiovascular biology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Endothelium-derived contracting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Protective effects of captopril against ischemic stress: role of cellular Mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Long-lasting mnemotropic effect of substance P and its N-terminal fragment (SP1-7) on avoidance learning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Influence of ACE inhibitors on free radicals and reperfusion injury: pharmacological curiosity or therapeutic hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Hypertension-associated hypalgesia. Evidence in experimental animals and humans, pathophysiological mechanisms, and potential clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

The cell biology of Heymann nephritis: a model of human membranous glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

The progression from hypertension to congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Medical intelligence drug therapy: captopril

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Duration of Action and Short-Term Hormonal Responses to Enalapril (MK 421) in Normal Subjects

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Prediction of sustained antihypertensive efficacy of chronic captopril therapy: Relationships to immediate blood pressure response and control plasma renin activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

DOCA-salt induced malignant hypertension in spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin converting enzyme inhibitors and cardiovascular remodelling

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Regression of left ventricular hypertrophy from systemic hypertension by enalapril

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Manipulation of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Comm

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Glomerular actions of angiotensin II

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Oxidative-nitrosative stress in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Is ACE Inhibition with Lisinopril Helpful in Diabetic Neuropathy?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Sensory nerve innervation of epineurial arterioles of the sciatic nerve containing calcitonin gene-related peptide: effect of streptozotocin-induced diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Mediation of vascular relaxation in epineurial arterioles of the sciatic nerve: effect of diabetes in type 1 and type 2 diabetic rat models.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Increased NADH-Oxidase–Mediated Superoxide Production in the Early Stages of Atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Are ACE inhibitors a "magic bullet" against oxidative stress?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Different effects of thiol and nonthiol ace inhibitors on copper-induced lipid and protein oxidative modification

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Magnesium deficiency and sudden death

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Cardiac fibrogenesis in magnesium deficiency: a role for circulating angiotensin II and aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II enhances thrombosis development in renovascular hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

A new paradigm for plaque stabilization

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Reinforcing effects of peripherally administered substance P and its C-terminal sequence pGlu6-SP6-11 in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Dynorphin A-(1-13) attenuates basal forebrain-lesion-induced amnesia in rats.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Dynorphin A (2-13) improves mecamylamine-induced learning impairment accompanied by reversal of reductions in acetylcholine release in rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Coordination of multiple memory systems

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Acetylcholine modulation of neural systems involved in learning and memory

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The renin-angiotensin system and malignancy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin receptors: a new role in cancer?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin II suppresses adriamycin-induced apoptosis through activation of phosphatidylinositol 3-kinase/Akt signaling in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Nonclassic endogenous novel [corrected] regulators of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Inflammation and angiotensin II.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin converting enzyme inhibitors for cancer treatment?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, and Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Antihypertensive therapy and the risk of malignancies

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Different effect of antihypertensive drugs on conduit artery endothelial function

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

ACE inhibitor potentiation of bradykinin-induced venoconstriction

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Activation of bradykinin B1 receptor by ACE inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The renin angiotensin system and nociception in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Treatment with enalapril modifies the pain perception pattern in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

ACE inhibitors and congenital anomalies

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Adverse reactions with angiotensin converting enzyme (ACE) inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Targeting brain AT1 receptors by RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

ACE inhibitors in cardiovascular disease--unbeatable?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Recent clinical trials with omapatrilat: new developments

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Bradykinin and the pathophysiology of angioedema

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Vasopeptidase inhibition: a double-edged sword?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Vasopeptidase inhibition and angio-oedema

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

The C‐type natriuretic peptide precursor of snake brain contains highly specific inhibitors of the angiotensin‐converting enzyme

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Ace revisited: a new target for structure-based drug design.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.184

7 January 2021

Identifiers

DOI

10.1038/HR.2009.184

1 reference

21 August 2017

1 reference

PubMed ID

19911001